| Q91918214 | A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology |
| Q47590406 | Adverse cardiac events in out-patients initiating clozapine treatment: a nationwide register-based study. |
| Q26744346 | Aggression in autism spectrum disorder: presentation and treatment options |
| Q38812942 | Areas of controversy in neuroprogression in bipolar disorder |
| Q92426910 | Bipolar depression: a major unsolved challenge |
| Q41440229 | Chlorpromazine as Prophylaxis for Bipolar Disorder with Treatment- and Electroconvulsive Therapy-Refractory Mania: Old Horse, New Trick |
| Q24186084 | Clozapine augmentation for treatment-resistant schizoaffective disorder |
| Q92403507 | Clozapine in Treatment-Resistant Bipolar Disorder With Suicidality. Three Case Reports |
| Q46893940 | Clozapine-induced myocarditis may be associated with rapid titration: A case report verified with autopsy |
| Q89154822 | Comprehensive comparison of monotherapies for psychiatric hospitalization risk in bipolar disorders |
| Q49453720 | Effective and underprescribed: what about clozapine? |
| Q54942040 | Effectiveness of Traditional Chinese Medicineas as an Adjunct Therapy for Refractory Schizophrenia: A Systematic Review and Meta Analysis. |
| Q90014717 | Effectiveness of clozapine, oxcarbazepine and rivastigmine combination in a bipolar disorder patient with initial cerebral atrophy |
| Q26795393 | Effectiveness of ultra-rapid dose titration of clozapine for treatment-resistant bipolar mania: case series |
| Q34676317 | Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology |
| Q35540723 | Functional and structural remodeling of glutamate synapses in prefrontal and frontal cortex induced by behavioral stress. |
| Q47618856 | Learned lessons from patients who take clozapine: A case study. |
| Q48008639 | NICE guidance: why not clozapine for treatment-refractory bipolar disorder? |
| Q48137161 | Neuron-glia interaction as a possible pathophysiological mechanism of bipolar disorder |
| Q64082308 | Psychiatric pharmacist's role in overcoming barriers to clozapine use and improving management |
| Q33878816 | Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review |
| Q38932319 | Suicidal Behavior in Mood Disorders: Response to Pharmacological Treatment |
| Q37613752 | Switching bipolar disorder patients treated with clozapine to another antipsychotic medication: a mirror image study |
| Q57031593 | Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study |
| Q37609756 | Use of clozapine alongside chemotherapy in a treatment-resistant bipolar disorder patient with ovarian carcinoma: A case report and brief review |